scholarly journals Primary Pulmonary Lymphoma with Superior Vena Cava Syndrome

2018 ◽  
Vol 1 (2) ◽  
pp. 131
Author(s):  
Alfian Nur Rosyid ◽  
Resti Yudhawati Meliana
Keyword(s):  
Superior Vena Cava ◽  
Superior Vena Cava Syndrome ◽  
Superior Vena ◽  
Vena Cava ◽  
Lymphoid Cells ◽  
Ct Guided ◽  
Primary Pulmonary Lymphoma ◽  
Pulmonary Lymphoma ◽  
Vena Cava Syndrome ◽  
The Right

Primary Pulmonary Lymphoma (PPL) is a clonal proliferation of lymphoid cells that involve one or two lungs (parenchyma and or bronchi. PPL is found in approximately 0.4% of all lymphoma cases and 3.6% of NHL cases. Five years survival rate at stage I and II is 90%, and 80% in stage III and IV. A 63-year-old male farmer presented with chief complaint of shortness of breath for one week before admission and preceded by coughing for a month, loss of appetite and night sweating. There was an abnormal physical examination on the right side of the chest with non-tender lymph node enlargements in the right supraclavicular and neck region and superior vena cava syndrome. CT guided FNAB suggesting NHL. Patient was treated with CHOP chemotherapy regiment. However, with high grade lymphoma, patient did not respond well.

scholarly journals Primary Pulmonary Lymphoma Presenting with Superior Vena Cava Syndrome in a Young Female

2017 ◽  
Vol 2017 ◽  
pp. 1-4
Author(s):  
Divya Salhan ◽  
Prakash Verma ◽  
Tun Win Naing ◽  
Ebad Ur Rehman ◽  
Saroj Kandel ◽  
...  
Keyword(s):  
Superior Vena Cava ◽  
Superior Vena ◽  
Vena Cava ◽  
B Cell Lymphoma ◽  
Young Female ◽  
Large B Cell Lymphoma ◽  
Primary Pulmonary Lymphoma ◽  
Pulmonary Lymphoma ◽  
Vena Cava Syndrome ◽  
The Right

Primary Pulmonary Diffuse Large B Cell Lymphoma (PPDLBCL) is an extremely rare entity, which exhibits an aggressive behavior by compressing local blood vessels. It represents only 0.04% of all lymphoma cases and is extremely rare in young age. We present a case of a primary pulmonary lymphoma with superior vena cava syndrome (SVCS) in a young female. 27-year-old African American female presented with fever, cough, and facial puffiness for 2 weeks and unintentional weight loss. Chest examination showed decreased breath sounds and dullness on percussion on right side. Labs were normal except for mild leukocytosis, high lactate, and lactate dehydrogenase. Chest X-ray showed a large right side infiltrate with pleural effusion but chest CT showed 10 × 14 × 16 cm mass in the right lung without hilar and mediastinal lymphadenopathy. CT guided biopsy of the right lung mass was done and large B cell lymphoma was diagnosed. She received “involved field radiation” because of the bulky tumor size and superior vena cava involvement prior to R-CHOP to which she responded well. PPDLBCL should be considered as one of the differentials in a young patient with a large lung mass, which needs timely diagnosis and management.

scholarly journals Sequential Treatment of Superior Vena Cava Syndrome Caused by of Non-small Cell Carcinoma Lung Cancer (NSCLC) with Vascular Stenting and Iodine-125 Implantation

2009 ◽  
Vol 8 (4) ◽  
pp. 281-287 ◽  
Author(s):  
Lianxiang Xiao ◽  
Zhenjia Li ◽  
Lebin Wu ◽  
Zengtao Sun ◽  
Xianghong Yu
Keyword(s):  
Superior Vena Cava ◽  
Superior Vena Cava Syndrome ◽  
Superior Vena ◽  
Symptom Relief ◽  
Vena Cava ◽  
Sequential Treatment ◽  
Endovascular Stenting ◽  
Ct Guided ◽  
Vena Cava Syndrome ◽  
Iodine 125

Feasibility and efficacy of sequentially performed endovascular stenting and Iodine-125 brachytherapy for malignant superior vena cava syndrome (SVCS) were evaluated. Thirty-four patients with malignant SVCS caused by NSCLC underwent sequential treatment of endovascular stenting and Iodine-125 brachytherapy. SVCS was diagnosed in all patients by CT images or vena-cavography. Pathology diagnosis was acquired by image guided biopsy. Endovascular stent placement was performed as first-line treatment for symptom relief. CT-guided Iodine-125 seed implantation performed 24hr after stenting. Clinical end points were resolution of symptoms and local efficacy of primary malignancy regression. Symptom relief rate was >90% after 24hr and 97% after 3 months. No migration of seeds or restenosis occurred in any patient. The local efficacy (defined as either partial or complete response) was 53%, 79%, 88% and 74% after 1, 3, 6 and 12months, respectively. Mean SVCS-free survival time was 305 days (range 120–960 days). Two patients were still alive at the time of this writing, Thirty-one died from progression and one died from acute heart disease. Sequentially performed endovascular stenting and Iodine-125 brachytherapy provides a safe and effective alternative for malignant SVCS caused by NSCLC.

scholarly journals Superior vena cava syndrome from an invasive thymoma with transcaval invasion to the right atrium

2016 ◽  
Vol 2016 (4) ◽  
pp. rjw044
Author(s):  
Ashwad Afzal ◽  
Ivan Wong ◽  
Aleksandr Korniyenko ◽  
Alex Ivanov ◽  
Berhane Worku ◽  
...  
Keyword(s):  
Superior Vena Cava ◽  
Right Atrium ◽  
Superior Vena Cava Syndrome ◽  
Superior Vena ◽  
Vena Cava ◽  
Invasive Thymoma ◽  
Vena Cava Syndrome ◽  
The Right

Fatal Pericardial Tamponade after Wallstent Implantation for Malignant Superior Vena Cava Syndrome

2002 ◽  
Vol 9 (5) ◽  
pp. 680-684 ◽  
Author(s):  
Matthias Martin ◽  
Iris Baumgartner ◽  
Martin Kolb ◽  
Jürgen Triller ◽  
Hans-Peter Dinkel
Keyword(s):  
Superior Vena Cava ◽  
Superior Vena Cava Syndrome ◽  
Rare Complication ◽  
Superior Vena ◽  
Vena Cava ◽  
Pericardial Tamponade ◽  
Stent Deployment ◽  
Stent Strut ◽  
Vena Cava Syndrome ◽  
The Right

Purpose: To report a rare, fatal complication of superior vena cava Wallstent implantation. Case Report: A 59-year-old man presenting with superior vena cava syndrome caused by small-cell lung cancer underwent stent implantation of 2 kissing Wallstents >1.5 cm above the right atrium. Despite correct stent deployment, vessel perforation occurred in a section not encased by tumor, which led to fatal pericardial tamponade shortly after the procedure. Autopsy revealed perforation of a stent strut through the caval wall into the pericardial space. Anatomical and methodological reasons are discussed. Conclusions: The interventionist should be aware of this rare complication. Alternative stent designs avoiding the sharp ends of Wallstents and Palmaz stents should be considered.

scholarly journals Chemotherapy taste and bronchospasm: a consequence of a fistula between the superior vena cava and the right main bronchi

2021 ◽  
Vol 2021 (7) ◽  
Author(s):  
Túlio Fabiano de Oliveira Leite ◽  
Lucas Vatanabe Pazinato ◽  
Joaquim Mauricio da Motta Leal Filho
Keyword(s):  
Interventional Radiology ◽  
Female Patient ◽  
Superior Vena Cava ◽  
Superior Vena Cava Syndrome ◽  
Superior Vena ◽  
Vena Cava ◽  
Bronchial Fistula ◽  
Vena Cava Syndrome ◽  
The Right

ABSTRACT A 56-year-old female patient with upper lobe neoplasia of the right lung and superior vena cava syndrome. The patient complained about the taste of the medications during the chemotherapy sessions. Interventional radiology diagnosed cava-bronchial fistula when it injected contrast into the inferior and superior vena cava.

Mediastinal chloroma affecting the right heart with superior vena cava syndrome

1994 ◽  
Vol 127 (2) ◽  
pp. 465-468 ◽  
Author(s):  
H Dingerkus ◽  
H Völler ◽  
A Albrecht ◽  
L Hennig ◽  
H Stein ◽  
...  
Keyword(s):  
Superior Vena Cava ◽  
Superior Vena Cava Syndrome ◽  
Superior Vena ◽  
Vena Cava ◽  
Right Heart ◽  
Vena Cava Syndrome ◽  
The Right
Sign in / Sign up

Export Citation Format

Share Document